State legislative tracker

Recent activity

• IL · HB 3502

  Illinois Obesity Treatment Coverage Act

  Passed one chamber

  Requires Illinois Medicaid (HealthChoices) to cover FDA-approved anti-obesity medications including GLP-1s for patients meeting clinical criteria. Removes prior-authorization step-therapy requirements.

  What this means for readers: House-passed. Senate Health Committee scheduled June 18. If enacted, Illinois would become one of the most progressive Medicaid programs for obesity treatment coverage.

  Sponsors: Rep. Cassidy

  Last action 2026-05-15 · Official tracker →

• CA · AB 1234

  California GLP-1 Coverage Equity Act

  In committee

  Would require Medi-Cal and California commercial plans regulated by DMHC to cover FDA-approved GLP-1 medications for weight management when prescribed for patients meeting clinical criteria (BMI ≥30 or ≥27 with comorbidity).

  What this means for readers: If enacted, would eliminate prior-authorization friction for ~14M California Medi-Cal enrollees and expand commercial mandate. Watch May 28 Health Committee hearing.

  Sponsors: Sen. Caballero, Asm. Bonta

  Last action 2026-05-10 · Official tracker →

• FL · HB 2204

  Florida Compounding Pharmacy Patient Safety Act

  Enacted

  Strengthens state oversight of 503A compounding pharmacies dispensing GLP-1 medications. Requires monthly lot testing for sterility and identity, mandatory adverse-event reporting within 72 hours, and pharmacist-of-record attestation.

  What this means for readers: Effective July 1, 2026. Florida compounded GLP-1 supply will tighten significantly; many high-volume operators expected to exit. Plan transition to branded or LillyDirect/NovoCare paths.

  Sponsors: Rep. Garcia

  Last action 2026-04-30 · Official tracker →

• TX · SB 451

  Texas Step Therapy Reform Act

  Passed one chamber

  Limits step-therapy requirements for FDA-approved obesity medications. Plans must approve PA within 72 hours for documented BMI ≥35 or ≥30 with comorbidity. 24-hour decisions for urgent cases.

  What this means for readers: Senate-passed, House Insurance Committee scheduled June 2026. If enacted, reduces typical PA delay from 1-4 weeks to 72 hours for Texas commercial enrollees.

  Sponsors: Sen. Hancock

  Last action 2026-04-22 · Official tracker →

• PA · SB 99

  Pennsylvania Patient Right-to-Switch Act

  Introduced

  Protects patients from mid-year formulary switches by commercial insurers. Plans cannot remove a GLP-1 medication from formulary or move to higher tier during plan year if a patient is currently filling that prescription.

  What this means for readers: Newly introduced. Targets the practice where insurers drop coverage mid-year, forcing patients to re-titrate on a different drug. Pennsylvania commercial enrollees with established GLP-1 prescriptions would gain stability.

  Sponsors: Sen. Cappelletti

  Last action 2026-04-02 · Official tracker →

• NY · A 1208

  New York Telehealth Parity Expansion Act

  In committee

  Codifies permanent interstate telehealth prescribing rules; requires commercial plans to reimburse telehealth-prescribed obesity treatment at the same rate as in-person consultations.

  What this means for readers: Would lock in COVID-era interstate telehealth flexibility permanently for New York. Removes uncertainty for platforms like Ro Body, Hims, Sequence operating in NY.

  Sponsors: Asm. Gottfried

  Last action 2026-03-15 · Official tracker →

All tracked bills